Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia (CCAP)
Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial
Sponsor: Thomas Benfield
Terminated
DSMB advise due to high probability of futility
Other COVID trials with similar outcome
Listed as NCT04345289, this PHASE3 trial focuses on COVID and Corona Virus Infection and remains terminated or withdrawn. Sponsored by Thomas Benfield, it has been updated 8 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Thomas Benfield
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Copenhagen, Denmark , Herlev, Denmark , Herning, Denmark , Hillerød, Denmark , Hvidovre, Denmark , Kolding, Denmark , Odense, Denmark , Roskilde, Denmark and 1 more location